Articles related to ANTITHROMBOTIC THERAPY

The FDA accepted asundexian’s secondary-stroke-prevention application for Priority Review, supported by phase 3 OCEANIC-STROKE results in noncardioembolic ischemic stroke.

First-line pulsed field catheter ablation outperformed antiarrhythmic drug therapy for rhythm control at one year in patients with persistent atrial fibrillation, with similar serious adverse event rates.

“The idea of preserving and reducing thrombosis without increasing bleeding is very, very exciting.” — Roxana Mehran, MD, SCAI 2025

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

Blood thinners interact with various medications and supplements, potentially increasing bleeding risk or reducing efficacy. Physicians should be aware of these interactions and educate patients on the importance of consulting healthcare professionals before taking new products.